Terns Pharmaceuticals Deal History & Licensing Activity
Terns Pharmaceuticals is a biotech headquartered in US. Over the past three years, Terns Pharmaceuticals has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals).
Deals (12mo)
1
Active Trials
4
Top Modality
Small Molecules
Focus Area
Hematology
Terns Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Terns Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| TERN-701 | Merck | Small Molecules | Phase 1 | acquisition | Mar 2026 |
Terns Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Terns Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Terns Pharmaceuticals Strategic Signals
Key indicators of Terns Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Terns Pharmaceuticals's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Hematology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Hematology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for hematology
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Terns Pharmaceuticals Licensing & Deal Activity
Terns Pharmaceuticals is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Terns Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Terns Pharmaceuticals include Hematology (2 deals and trials). In terms of modality, Terns Pharmaceuticals has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Terns Pharmaceuticals and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Terns Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.